Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Open access
Chapeau, Emilie A., Sansregret, Laurent, Galli, Giorgio G., Chène, Patrick, Wartmann, Markus, Mourikis, Thanos P., Jaaks, Patricia, Baltschukat, Sabrina, Barbosa, Ines A. M., Bauer, Daniel, Brachmann, Saskia M., Delaunay, Clara, Estadieu, Claire, Faris, Jason E., Furet, Pascal, Harlfinger, Stefanie, Hueber, Andreas, Jiménez Núñez, Eloísa, Kodack, David P., Mandon, Emeline, Martin, Typhaine, Mesrouze, Yannick, Romanet, Vincent, Scheufler, Clemens, Sellner, Holger, Stamm, Christelle, Sterker, Dario, Tordella, Luca, Hofmann, Francesco, Soldermann, Nicolas, Schmelzle, Tobias · 2024 · Nature Cancer

Abstract

The YAP–TEAD protein–protein interaction mediates YAP oncogenic functions downstream of the Hippo pathway. To date, available YAP–TEAD pharmacologic agents bind into the lipid pocket of TEAD, targeting the interaction indirectly via allosteric changes. However, the consequences of a direct pharmacological disruption of the interface between YAP and TEADs remain largely unexplored. Here, we present IAG933 and its analogs as potent first-in-class and selective disruptors of the YAP–TEAD protein–protein interaction with suitable properties to enter clinical trials. Pharmacologic abrogation of the interaction with all four TEAD paralogs resulted in YAP eviction from chromatin and reduced Hippo-mediated transcription and induction of cell death. In vivo, deep tumor regression was observed in Hippo-driven mesothelioma xenografts at tolerated doses in animal models as well as in Hippo-altered cancer models outside mesothelioma. Importantly this also extended to larger tumor indications, such as lung, pancreatic and colorectal cancer, in combination with RTK, KRAS-mutant selective and MAPK inhibitors, leading to more efficacious and durable responses. Clinical evaluation of IAG933 is underway.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43018-024-00754-9

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Metadata

Authors
Chapeau, E. A., Sansregret, L., Galli, G. G., Chène, P., Wartmann, M., Mourikis, T. P., Jaaks, P., Baltschukat, S., Barbosa, I. A. M., Bauer, D., Brachmann, S. M., Delaunay, C., Estadieu, C., Faris, J. E., Furet, P., Harlfinger, S., Hueber, A., Jiménez Núñez, E., Kodack, D. P., Mandon, E., Martin, T., Mesrouze, Y., Romanet, V., Scheufler, C., Sellner, H., Stamm, C., Sterker, D., Tordella, L., Hofmann, F., Soldermann, N., & Schmelzle, T.
Venue
Nature Cancer
Published
2024-04-02
Volume
5
Issue
7
Pages
1102-1120
ISSN
2662-1347 (ISSN-L)
OpenAlex
W4393397191
Cited by
159
References
18
FWCI
30.20
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers. https://app.cochat.ai/papers/10.1038/s43018-024-00754-9
The paper
Chapeau, E. A., Sansregret, L., Galli, G. G., Chène, P., Wartmann, M., Mourikis, T. P., Jaaks, P., Baltschukat, S., Barbosa, I. A. M., Bauer, D., Brachmann, S. M., Delaunay, C., Estadieu, C., Faris, J. E., Furet, P., Harlfinger, S., Hueber, A., Jiménez Núñez, E., Kodack, D. P., . . . Schmelzle, T. (2024). Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers. Nature Cancer. https://doi.org/10.1038/s43018-024-00754-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.